Table 1

Distribution of the subjects within groups, characteristics and vascular density

		Control group	Group 1—mild disease	Group 2—moderate disease	Group 3—severe disease	Significance among all groups
Gender	Male	10	12	10	12	0.520*
Gender	Female	17	12	14	9	0.520*
Age (years)	Mean	39	41	42	44	0.333†
Diabetes	No	27	24	22	19	0.189*
Diabetes	Yes	0	0	2	2	0.189*
Smoker	No	22	21	24	19	0.186*
Smoker	Yes	5	3	0	2	0.186*
Race	Caucasic	27	23	19	11	0.001*§
	Latin	0	1	5	9
	Other	0	0	0	1
ACEI use	No	26	24	24	20	0.550*
ACEI use	Yes	1	0	0	1	0.550*
Days from PCR	Mean	–	–	72	70	–
Central VD	Mean	16.90	17.16	13.37	13.63	0.000†§
Central VD	SD	3.10	3.48	4.90	3.78	0.000†§
Inferior VD	Mean	50.37	49.55	49.67	48.78	0.827‡
Inferior VD	SD	3.25	2.63	4.88	4.56	0.827‡
Superior VD	Mean	49.72	48.82	49.03	49.46	0.733†
Superior VD	SD	3.43	2.99	2.70	3.28	0.733†
Nasal VD	Mean	43.92	44.26	43.86	44.21	0.970†
Nasal VD	SD	2.59	4.41	2.80	7.74	0.970†
Temporal VD	Mean	47.77	45.99	48.41	47.87	0.020‡§
Temporal VD	SD	2.20	3.46	4.19	3.97	0.020‡§
FAZ	Mean	0.25	0.20	0.35	0.31	0.000‡
FAZ	SD	0.07	0.08	0.15	0.10	0.000‡
Image quality	Mean	64,96	64.13	66,88	65,95	0.441‡
Image quality	SD	5,21	6,61	4,25	4,75	0.441‡

*Χ² test.
†ANOVA test and Bonferroni correction.
‡Kruskal-Wallis and Mann-Whitney U test.
§Statistically significant p<0.05.
ACEI, ACE inhibitor; ANOVA, analysis of variance; FAZ, foveal avascular zone; VD, vascular density.